Regulatory Approval

GlaxoSmithKline PLC
18 November 2003

    GlaxoSmithKline Receives US Approval of Advair Diskus(R) 250/50 for the
              Treatment of COPD associated with Chronic Bronchitis

London, UK, November 18, 2003 - GlaxoSmithKline announced today that Advair
Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol inhalation powder
50 mcg) has been approved by the US Food and Drug Administration for use in COPD
patients with chronic bronchitis.

COPD, or chronic obstructive pulmonary disease, is a serious and debilitating
lung disease that affects an estimated 20 million Americans. Many people with
COPD have associated chronic bronchitis.

"We anticipate that this approval will be welcome news for patients and
physicians," said Chris Viehbacher, President, US Pharmaceuticals. "Advair
Diskus is an important new treatment option for this condition and it offers a
new approach to treating this widespread and complex lung disease."

Advair Diskus 250/50 is indicated for the maintenance treatment of airflow
obstruction in patients with COPD associated with chronic bronchitis.

S M Bicknell

Company Secretary

18 November 2003



About GlaxoSmithKline

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and
healthcare companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer.

Enquiries:
UK Media enquiries:                                  Martin Sutton                 [phone]
                                                     David Mawdsley                [phone]
                                                     Chris Hunter-Ward             [phone]
US Media enquiries:                                  Nancy Pekarek                 [phone]
                                                     Mary Anne Rhyne               [phone]
                                                     Patty Seif                    [phone]
European Analyst/Investor enquiries:                 Duncan Learmouth              [phone]
                                                     Anita Kidgell                 [phone]
                                                     Philip Thomson                [phone]
US Analyst/Investor enquiries:                       Frank Murdolo                 [phone]
                                                     Tom Curry                     [phone]


                      This information is provided by RNS
            The company news service from the London Stock Exchange